WO2010132370A8 - Soluble trem-1 family peptides and methods of use - Google Patents

Soluble trem-1 family peptides and methods of use Download PDF

Info

Publication number
WO2010132370A8
WO2010132370A8 PCT/US2010/034263 US2010034263W WO2010132370A8 WO 2010132370 A8 WO2010132370 A8 WO 2010132370A8 US 2010034263 W US2010034263 W US 2010034263W WO 2010132370 A8 WO2010132370 A8 WO 2010132370A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
family peptides
soluble trem
peptides
trem
Prior art date
Application number
PCT/US2010/034263
Other languages
French (fr)
Other versions
WO2010132370A2 (en
WO2010132370A3 (en
Inventor
Daniel W. Mc Vicar
A. Valance Washington
Jessica Morales
Original Assignee
Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services filed Critical Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Publication of WO2010132370A2 publication Critical patent/WO2010132370A2/en
Publication of WO2010132370A8 publication Critical patent/WO2010132370A8/en
Publication of WO2010132370A3 publication Critical patent/WO2010132370A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides compositions including sTLT-1 and sTREM-1 polypeptides, the use of such polypeptides in therapeutic methods, and kits including such peptides.
PCT/US2010/034263 2009-05-11 2010-05-10 Soluble tlt-1 for the treatment and diagnosis of sepsis WO2010132370A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17724209P 2009-05-11 2009-05-11
US61/177,242 2009-05-11

Publications (3)

Publication Number Publication Date
WO2010132370A2 WO2010132370A2 (en) 2010-11-18
WO2010132370A8 true WO2010132370A8 (en) 2011-08-11
WO2010132370A3 WO2010132370A3 (en) 2011-09-29

Family

ID=42985622

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/034263 WO2010132370A2 (en) 2009-05-11 2010-05-10 Soluble tlt-1 for the treatment and diagnosis of sepsis

Country Status (1)

Country Link
WO (1) WO2010132370A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
NZ602845A (en) * 2010-04-08 2015-05-29 Inst Nat Sante Rech Med Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof
LT2814844T (en) 2012-02-15 2017-10-25 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
WO2013120554A1 (en) 2012-02-15 2013-08-22 Novo Nordisk A/S Antibodies that bind peptidoglycan recognition protein 1
MY178347A (en) 2014-07-17 2020-10-08 Novo Nordisk As Site directed mutagenesis of trem-1 antibodies for decreasing viscosity
EP3423493A2 (en) 2016-03-04 2019-01-09 Alector LLC Anti-trem1 antibodies and methods of use thereof
JOP20190248A1 (en) 2017-04-21 2019-10-20 Amgen Inc Trem2 antigen binding proteins and uses thereof
PE20201343A1 (en) 2018-04-02 2020-11-25 Bristol Myers Squibb Co ANTI-TREM-1 ANTIBODIES AND USES OF THEM
CN113692415A (en) 2019-04-17 2021-11-23 诺和诺德股份有限公司 Bispecific antibodies
CN113755580B (en) * 2021-09-13 2023-10-27 中国医学科学院阜外医院 Pharmaceutical intervention target for treating and/or relieving lymphedema and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040180409A1 (en) * 2003-03-16 2004-09-16 Mcvicar Daniel TLT-1, a novel platelet-associated receptor and uses therefor
US7553936B2 (en) * 2006-12-04 2009-06-30 The United States of America as represented by Secretary Department of Health and Human Services Anti-TREM-like transcript-1 (TLT-1) antibodies and compositions
EP2796878A1 (en) * 2008-05-23 2014-10-29 Biocartis NV New biomarkers for diagnosis, prediction and/or prognosis of sepsis and uses thereof

Also Published As

Publication number Publication date
WO2010132370A2 (en) 2010-11-18
WO2010132370A3 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
WO2010132370A8 (en) Soluble trem-1 family peptides and methods of use
WO2008121767A3 (en) Stitched polypeptides
HRP20181353T1 (en) The tuberculosis rv2386c protein, compositions and uses thereof
WO2011047087A3 (en) Protein detection via nanoreporters
WO2009100255A3 (en) Modified leptin polypeptides and their uses
WO2010034032A3 (en) Methods for preparing purified polypeptide compositions
WO2012020006A3 (en) Anti-fap antibodies and methods of use
MX345909B (en) Anti-fgfr3 antibodies and methods using same.
WO2010011735A3 (en) Modified bovine g-csf polypeptides and their uses
WO2012076293A9 (en) Formulations comprising polysiloxanes having nitrogen-containing groups
IL209277A0 (en) Human anti-il-6/il-6r antibodies, compositions comprising the same and uses thereof
WO2011142858A3 (en) Chlorotoxin variants, conjugates, and methods for their use
MX2009008430A (en) Anti-robo4 antibodies and uses therefor.
WO2008060705A3 (en) Anti-dll4 antibodies and methods using same
WO2011072099A3 (en) Compositions and methods comprising protease variants
WO2010065969A8 (en) Sparc binding scfcs
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
WO2012024452A3 (en) Modified relaxin polypeptides and their uses
WO2012064792A3 (en) Protein complexes for antigen binding and methods of use
WO2010096604A3 (en) Uses of cancer-targeting peptides in cancer diagnosis
MX2012000396A (en) Methods and compositions for use in cellular therapies.
WO2010136483A3 (en) Antigen-binding proteins
WO2009120380A3 (en) Recombinant rhinovirus vectors
WO2009152167A3 (en) Delivery of therapeutics
WO2011050188A8 (en) Anti-hepsin antibodies and methods using same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10720070

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10720070

Country of ref document: EP

Kind code of ref document: A2